Memo fra CEO Svein Lien

Kjære aksjonærer

På grunn av mange forespørsler tilknyttet diverse diskusjonsforum og sosiale medier, er det besluttet at jeg som administrerende direktør skal gi en personlig redegjørelse som forhåpentligvis rydder opp i noen av uklarhetene som presenteres og diskuteres.

Jeg bringer ikke ny informasjon i det følgende, men presenterer det i en ny kontekst som kanskje kan være nyttig og til hjelp for enkelte allikevel.

La meg først ta litt historie. Jeg kom inn i Biotec som leder våren 2010. Selskapets situasjon var i … continue reading »

Biotec appeals UK Drug Tariff rejection

(Tromsø, 19 May 2017) Biotec Pharmacon ASA’s (”Biotec”, OSE: BIOTEC) subsidiary Biotec BetaGlucans has today filed an appeal for rejection of UK Drug Tariff reimbursement

With support from external advisors, Biotec has evaluated the decision by the Drug Tariff authority under NHS to reject the application for remuneration of Woulgan for wound treatment in UK, and concluded that there are good reasons for appeal within the framework of NHS’ own guidelines.

-“We have consulted with specialist UK healthcare lawyers regarding the application. … continue reading »

Patent on technology platform SBG granted Biotec Pharmacon in the US

Biotec Pharmacon ASA (OSE: BIOTEC)  has been granted patent in the US for the technology platform of gel forming Soluble Beta-Glucan (SBG).

The granted patent US 9,623,043 title of invention: Glucan. The claims cover the method for producing a gel forming SBG and the product obtainable by this method as well as the medical use of the glucan gel. The patent is valid to 2031

“We are very pleased with this patent as it secures our intellectual property in the important … continue reading »

UK Drug Tariff rejects current Woulgan application

Biotec Pharmacon ASA’s (”Biotec”, OSE: BIOTEC) subsidiary Biotec Betaglucan has received negative feedback from UK Drug Tariff regarding application for reimbursement.

The UK Drug Tariff has in a letter of May 2nd informed Biotec Pharmacon that the NHS has decided not to list Woulgan based on its current application because they consider the evidence provided to be insufficient to document cost effectiveness.

The management are considering if there are grounds for an appeal in line with the NHS’ own guidelines and will … continue reading »

Biotec Pharmacon: Results for Q1 2017

(Tromsø, 27 April 2017) Biotec Pharmacon ASA (”Biotec”, OSE: BIOTEC) reported sales of NOK 18.2 million (17.3) in the first quarter of 2017, and a negative EBITDA of NOK 4.1 million (-3.5). Woulgan® generated sales of NOK 0.4 million during the first quarter primarily to Germany. ArcticZymes continued its positive sales growth from the previous quarters

We see that Woulgan® continues to generate revenues in Germany and based on the positive market feedback from the evaluations, we remain optimistic for this … continue reading »

Invitation to presentation of Q1 2017 results

Biotec Pharmacon presents its report for the first quarter 2017 on Thursday, 27 April 2017

The presentation will be given by CEO Svein Lien, MD ArcticZymes Jethro Holter and VP Marketing Woulgan Stuart Devine.

The presentation starts at 08:30 a.m. and will be in English.

Venue: Hotell Continental, Stortingsgata 24, Oslo.

The presentation can also be followed as a live webcast from Hegnar TV on or It will be possible to post questions through the webcast console.

The interim report for the first quarter 2017 will be available on … continue reading »

Notice of ordinary general meeting

The ordinary general meeting in Biotec Pharmacon will be held on Thursday 11. May 2017 at 13.00 CET at Hotel Continetal, Stortingsgata 24, Oslo

Please find enclosed the notice and agenda for the meeting. The notice and registration and proxy form will be sent to the Company’s shareholders today and made available here.

Shareholders who wish to attend the annual general meeting, in person or by proxy, are requested to complete the registration form by Wednesday 10 May 2017 at noon.

The … continue reading »

Woulgan® Gel registered as a Class 1 exempt by the FDA in the USA

Biotec Pharmacon ASA’s (”Biotec”, OSE: BIOTEC) subsidiary Biotec Betaglucans has received positive confirmation by the FDA that Woulgan® Gel is listed as a Class 1 exempt in the USA

Woulgan® Gel is registered as a Class 1 exempt by the FDA in the USA. This means that Woulgan® can be imported and used in the country. However, in order to receive favourable reimbursement a more advanced classification will be needed and Biotec is currently working to clarify the optimal route and strategy.

The … continue reading »